Physician profile
Roger Wayne Schultz
NPI 1194708974
$1,083.53
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $16.53 · 2021: $51.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $218.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $214.75 | 2019-2021 | |
| Glaxosmithkline, LLC. | $188.56 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $113.94 | 2019 | |
| Novo Nordisk INC | $96.23 | 2019 | |
| Amarin Pharma, INC. | $60.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $55.28 | 2019 | |
| Abbvie INC. | $37.37 | 2021 | |
| Horizon Therapeutics Plc | $26.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.00 | 2019 | |
| Merck Sharp & Dohme LLC | $19.14 | 2019 | |
| Pfizer INC. | $17.50 | 2019 | |
| Neotract INC. | $14.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.